Metastatic Urothelial Carcinoma Clinical Trial
Official title:
A Phase II Trial of Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing Patients With Metastatic Urothelial Carcinoma
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
The combination of Pembrolizumab + sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of sEphB4-HSA will be given at Day 1, 8, and 15 of each 3 week cycle. Each cycle of Pembrolizumab will be given at Day 1 of each 3 week cycle. Participants may continue on study protocol as long as they continue to respond and remains clinically stable on study medication. Patients may come off treatment for the following reasons: - Disease progression. - If tumor resolves. - For participants who become pregnant. - Incidence or severity of adverse drug reaction in this or other studies indicates a potential health hazard to subjects. - Patient withdraws consent. - Study termination by the Sponsor. - Participants who are non-compliant with respect to taking drugs, keeping appointments, or having tests required for the evaluation of drug safety and efficacy. - Participant's condition renders them unacceptable for further treatment in the judgment of the investigator. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05700344 -
SOGUG-AVELUMAB_RWD
|
||
| Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT04953104 -
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
|
Phase 2 | |
| Withdrawn |
NCT06050954 -
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
|
Phase 2 | |
| Active, not recruiting |
NCT03534804 -
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00365157 -
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT06018116 -
A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
|
Phase 2 | |
| Recruiting |
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04936230 -
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Terminated |
NCT03115801 -
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT03854474 -
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02693717 -
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
|
Phase 2 | |
| Recruiting |
NCT04848519 -
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04724018 -
Sacituzumab Govitecan Plus EV in Metastatic UC
|
Phase 1 | |
| Terminated |
NCT04003610 -
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
|
Phase 2 | |
| Recruiting |
NCT04383067 -
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
|
Phase 2 | |
| Not yet recruiting |
NCT03108261 -
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
|
Phase 2 |